

Cite this: *RSC Adv.*, 2015, 5, 14747

Positive and negative allosteric effects of thiacalix[4]arene-based receptors having urea and crown-ether moieties†

Hirotsugu Tomiyasu,^a Jiang-Lin Zhao,^a Xin-Long Ni,^b Xi Zeng,^b Mark R. J. Elsegood,^c Beth Jones,^c Carl Redshaw,^d Simon J. Teat^e and Takehiko Yamato^{*a}

Heteroditopic receptors (**4a–e**) based on a thiacalix[4]arene in the 1,3-*alternate* conformation, which have two urea moieties linking various phenyl groups substituted with either electron-donating or -withdrawing groups at their *m*-, or *p*-positions with a crown-ether moiety at the opposite side of the thiacalix[4]arene cavity, have been synthesized. The two examples with *p*-CH₃- (**4b**) and *p*-NO₂-substituted (**4e**) phenyl groups have been characterized by X-ray crystallography. The binding properties of receptor **4e** were investigated by means of ¹H NMR spectroscopic and absorption titration experiments in CHCl₃–DMSO (10 : 1, v/v) solution in the presence of K⁺ ions and various anions. Interestingly, it was found that receptor **4e**, which possesses two *p*-nitrophenyl ureido moieties, can complex most efficiently in the urea cavity or the crown-ether moiety; and the plausible allosteric effect of receptor **4e** was also studied.

Received 6th December 2014

Accepted 22nd January 2015

DOI: 10.1039/c4ra15905e

www.rsc.org/advances

Introduction

The use of calix[*n*]arenes¹ as building blocks for receptors capable of the highly selective recognition of cations, anions or neutral molecules has received considerable attention in the field of supramolecular chemistry. Among the various kinds of calix[*n*]arenes available, thiacalix[4]arenes^{2,3} are proving to be competent scaffolds and are finding wide use, for example as chemosensors, as well as in catalysis because of their favourable conformational properties, easy functionalization and emerging metal coordination chemistry. Several kinds of systems based on thiacalix[4]arenes are suitable for allosteric regulation⁴ of host–guest interactions with metal cations, and these contribute greatly to organic processes in biological systems. Anions also play an important role in biological processes, and are closely related with biological systems such as DNA and enzyme substrates. The development and the investigation of anion selective sensors⁵ have attracted

considerable interest. However, it is more difficult to accomplish compared with metal cation sensors because anions can possess structures of different shapes,⁶ typically spherical (F[−], Cl[−], Br[−], I[−]), Y-shaped (AcO[−], PhCOO[−]) or tetrahedral (H₂PO₄[−]). In recent years, anion receptors based on calix[*n*]arenes have become an active research topic. Calix[*n*]arene urea derivatives are efficient for anion recognition given the hydrogen-bonding interaction between anions and N–H protons which can occur.

Colorimetric chemosensors^{7,8} have also attracted attention due to some desirable features such as easy detection by the naked eye, construction of simple, low-cost devices and so on. Many colorimetric anion receptors containing a variety of chromogenic signaling units such as indole, imidazolium, benzenediimide, 4-nitrophenylazo, diazo and anthraquinone groups have been developed. Furthermore, numerous colorimetric anion sensors utilizing a variety of structural scaffolds, which contain urea groups, have been investigated and proved to be efficient naked-eye detectors for various anions. However, there are a few reports on the development of colorimetric chemosensors based calix[4]arene type scaffolds.^{8I,P}

Lhoták⁹ and co-workers have reported anion receptors based on either an upper rim substituted calix[4]arene or thiacalix[4]arene, which contains two *p*-nitrophenyl or *p*-tolyl ureido moieties.^{9a–c,h} These anion receptors exhibited effective recognition abilities towards selected anions in common organic solvents. Moreover, Kumar¹⁰ and co-workers reported an anion receptor bearing a calix[4]arene in the 1,3-*alternate* conformation, which contains two *p*-nitrophenyl moieties.^{10g} This compound exhibited strong binding and good selectivity for Cl[−] ion due to the formation of

^aDepartment of Applied Chemistry, Faculty of Science and Engineering, Saga University, Honjo-machi 1, Saga 840-8502, Japan. E-mail: yamatot@cc.saga-u.ac.jp

^bKey Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou Province, Guizhou University, Guiyang, Guizhou, 550025, China

^cChemistry Department, Loughborough University, Loughborough LE11 3TU, UK

^dDepartment of Chemistry, The University of Hull, HU6 7RX, UK

^eALS, Berkeley Lab, 1 Cyclotron Road, Berkeley, CA 94720, USA

† Electronic supplementary information (ESI) available: Details of the ¹H/¹³C NMR spectra, ¹H NMR spectroscopic and UV-vis titration experimental data, the Bensei–Hilderbrand plot and Job's plot. CCDC 1026081 and 1026090. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4ra15905e

strong hydrogen bonds between the Cl^- ion and N–H protons in common organic solvents. However, investigations concerning the appearance of an allosteric effect in analogues based on the interaction of thiacalix[4]arene and alkali metal cations and anions has not yet been reported.


Herein, we have independently designed a heterodimeric system¹¹ based on a thiacalix[4]arene having two different side arms, *viz* two ureas moieties linking various phenyl groups bearing either electron-donating or -withdrawing groups at their *m*-, or *p*-positions. The calixarene also has a crown ether moiety at the opposite side of the thiacalix[4]arene cavity. We herein put forward the hypothesis (and then demonstrate) that the heterodimeric system, which is controlled by the complexation of the opposing side arms with anions and K^+ ion, exhibits effective positive and negative allosteric effects.

Results and discussions

Synthesis

The *O*-alkylation of *distal*-1 was carried out with 1.5 equivalents of tetraethyleneglycol ditosylate in the presence of an equivalent of K_2CO_3 according to the reported procedure, and afforded the desired 1,3-*alternate*-2 in 83% yield.¹² The hydrazinolysis of 1,3-*alternate*-2 was carried out with a large excess of hydrazine hydrate, and afforded the desired 1,3-*alternate*-3 in 86% yield. The condensation of 1,3-*alternate*-3 with 2.2 equivalents of the appropriate isocyanate in THF furnished the receptors **4a–e** in good to excellent yields (Scheme 1). In general, the ^1H NMR spectrum of receptors **4a–e** in CDCl_3 –DMSO (10 : 1, v/v) exhibited the characteristics of a 1,3-*alternate* conformation such as two singlets (18H each) for the *tert*-butyl protons, one singlet (4H) for OCH_2CO protons, two singlets (4H each) for aromatic protons and two singlets (2H each) for four urea NH protons.

The molecular structures of receptors **4b** and **4e** were also verified by X-ray crystallographic analysis (Fig. 1 and S15 and S16†). Receptors **4b** and **4e** were recrystallized from a mixture of CHCl_3 – CH_3CN (1 : 1, v/v) by slow evaporation. These results indicate that receptors **4b** and **4e** adopt the 1,3-*alternate*



Scheme 1 Synthesis of receptors 1,3-*alternate*-**4a–e**.




Fig. 1 X-ray crystal structure of receptor **4e**. H-bonds shown as dashed lines. One of two similar molecules in the asymmetric unit is shown in two orientations rotated by approx. 90°. H atoms not involved in H-bonding, minor disorder components, and chloroform molecules of crystallization are omitted for clarity.



Table 1 Association constants of receptor **4_{a–e}** with Cl[−] ions^{a,b}

Host	4_a	4_b	4_c	4_d	4_e
R	H	<i>p</i> -CH ₃	<i>p</i> -CF ₃	3,5-(CF ₃) ₂	<i>p</i> -NO ₂
<i>K_a</i> [M ^{−1}]	6816 ± 545	3021 ± 242	12 813 ± 1025	6945 ± 625	34 411 ± 2400

^a Measured in CDCl₃–DMSO (10 : 1, v/v) at 298 K by the ¹H NMR titration method using the chemical-shift change of the NH_a proton (Fig. S17–S22); host concentration was 4.0 × 10^{−3} M. ^b Guests used: Bu₄NCl.




Fig. 2 UV-vis absorption spectra of receptor **4_e** (2.5 μM) upon the addition of Bu₄NCl (0–50 μM) in CH₂Cl₂–DMSO (10 : 1, v/v).




Fig. 3 Binding mode of receptor **4_e** upon complexation with Cl[−] ions.

conformation in the solid state. There are two thiacalixarenes, one water molecule and three chloroform molecules in the asymmetric unit. Interestingly, it was found that two urea groups approach each other and are oriented in parallel due to the existence of dual intramolecular hydrogen bonding (in case of receptor **4_e**, for the molecule shown: N(14)–H(14)⋯O(21) 2.37(2); N(15)–H(15)⋯O(21) 2.05(2) Å; for the second molecule: N(2)–H(2)⋯O(10) 2.37, N(3)–H(3)⋯O(10) 1.94(2) Å) (Fig. 1 and S16†). Moreover, the thiacalix[4]-arene-monocrown-5 has a three-dimensional cavity and is large enough to accommodate the metal cation. The association constants (*K_a* values) between the receptors **4_{a–e}** and Cl[−] ion were determined by ¹H NMR spectroscopic titration experiments (Table 1). These results suggest that the association constants depend on the electron-donating/withdrawing groups located at the *m*-, or *p*-positions. In the presence of the electron-withdrawing groups, such as CF₃ (receptors **4_c** and **4_d**) and NO₂ (receptor **4_e**), the *K_a* values were greater than that for the unsubstituted receptor (receptor **4_a**). In contrast, in the case of receptor **4_b**, possessing the electron-donating Me group, there was a general decrease in the *K_a* value upon complexation with Cl[−] ion in comparison with the unsubstituted receptor **4_a**. Therefore, the introduction of electron-withdrawing groups at the *m*-, or *p*-positions appears to increase the acidity of the urea protons, and hence enhance the anion-binding ability through hydrogen-bonding interactions. The *K_a* value of receptor **4_e** with the electron-withdrawing NO₂ group at the *p*-position was the best out of all the *K_a* values measured for receptors **4_{a–e}** and Cl[−] ion. Interestingly, it was found that the *K_a* value of receptor **4_c**

with the electron-withdrawing CF₃ group at the *p*-position was greater than that of receptor **4_d** with the electron-withdrawing CF₃ group at the *m*-position. This result indicates that electron-withdrawing groups located at the *p*-position can significantly influence the acidity of the urea protons by conjugating with the phenyl groups. From the above, it is clear that receptor **4_e** with the electron-withdrawing NO₂ group at the *p*-position has the most effective recognition ability toward selected anions. Given this, further complexation studies of receptor **4_e** (2.5 μM) exhibits an absorption band at 310 nm in the UV spectrum in the absence of anions. Upon addition of Cl[−] ion (0–50 μM) to the solution of receptor **4_e**, Fig. 2 reveals a gradual decrease in the absorption of the band at 310 nm with a simultaneous increase in the absorption at 340 nm. Meanwhile, a clear isosbestic point was observed at 322 nm for the receptor **4_e**. A Job's plot binding between the receptor **4_e** and Cl[−] ion reveals a 1 : 1 stoichiometry (Fig. S25†), whilst the association constant (*K_a* value) for the complexation with Cl[−] ion by receptor **4_e** was determined to be 34 152 M^{−1} by UV-vis titration experiments in CHCl₃–DMSO (10 : 1, v/v) (Fig. S24, S27–S31†). Moreover, the concentration dependence of the ¹H NMR chemical shifts of the ureido protons in receptor **4_e** was not observed (Fig. S23†). This result suggests that receptor **4_e** has a strong intramolecular hydrogen bond between the two ureas linking the *p*-nitrophenyl moieties. These results strongly suggested that Cl[−] ion recognition by receptor **4_e** was *via* a hydrogen-bonding interaction between the Cl[−] ion and N–H protons as



Table 2 Association constants of receptor **4_e** with various anions^{a,b}

Anion	F [−]	Cl [−]	Br [−]	I [−]	AcO [−]	PhCO ₂ [−]	H ₂ PO ₄ [−]
Shape	Spherical	Spherical	Spherical	Spherical	Y-shape	Y-shape	Tetrahedral
K _a [M ^{−1}]	128 775 ± 10 302	34 152 ± 2732	7296 ± 584	4540 ± 363	107 298 ± 8584	106 743 ± 8539	108 687 ± 8695

^a Measured in CH₂Cl₂–DMSO (10 : 1, v/v) at 298 K by UV-vis titration method (Fig. 2, 4, S24 and S27–S31); host concentration was 2.5 μM. ^b Guests used: tetrabutylammonium salt.




Fig. 4 UV-vis absorption spectra of receptor **4_e** (2.5 μM) upon the addition of Bu₄NF (0–50 μM) in CH₂Cl₂–DMSO (10 : 1, v/v).




Fig. 5 Partial ¹H NMR spectra of receptor **4_e**/guest (*H/G* = 1 : 1); free receptor **4_e** and in the presence of 1 equiv. of Bu₄NX (*X* = F, Cl, Br, I, AcO, PhCOO, H₂PO₄). Host concentration was 2.5 μM. Solvent: CDCl₃–DMSO (10 : 1, v/v). 300 MHz at 298 K. *Denotes the solvent peak.

shown in Fig. 3. Similarly, the UV-vis titration experiments of receptor **4_e** with other various anions besides Cl[−] ion were carried out, and the *K_a* values are summarized in Table 2. As a result, it was found that receptor **4_e** exhibited high selectivity towards F[−] ion amongst all of the anions tested, and was capable of complexing with all of the anions tested, irrespective of their shape. Interestingly, the color of the receptor **4_e** solution changed from colorless to dark yellow upon addition of F[−] ion (5 equivalents), and this could be easily observed by the naked eye. Upon the addition of F[−] ions (0–50 μM) to the solution of the




Fig. 6 Proposed positive allosteric behaviour of receptor **4_e** with Br[−] and K⁺ ions. Partial ¹H NMR spectra of **4_e**/guest (*H/G* = 1 : 1): (a) free **4_e**; (b) **4_e** ⊃ KSO₃CF₃; (c) Bu₄NBr ⊃ [**4_e** ⊃ K⁺]; (d) **4_e** ⊃ Bu₄NBr. Solvent: CDCl₃–DMSO (10 : 1, v/v). 300 MHz at 298 K. *Denotes the solvent peak.

receptor **4_e**, the absorption peak at 342 nm gradually moved to a longer wavelength, finally reaching a maximum value at 360 nm (Fig. 4 and S26†). This result suggests that the quinoid structure was formed by the deprotonation of urea NH groups in the *p*-nitrophenyl ureido moiety. Moreover, the addition of F[−], AcO[−], PhCOO[−] or H₂PO₄[−] (1 equivalent) to solutions of receptor **4_e** in CHCl₃–DMSO (10 : 1, v/v) during the ¹H NMR titration experiments resulted in the disappearance of the urea proton signals, NH_a and NH_b (Fig. 5). These results indicate that strong interactions between these anions and the urea NH groups in the receptor **4_e** occur and that the kinetics of these anion exchanges is on the NMR time scale. On the other hand, ¹H NMR spectroscopic and UV-vis titration experiments of receptor **4_e** with K⁺ ion at the crown-ether moiety were also carried out (Fig. S32 and S33†). When only K⁺ ion (1 equivalent) were added, not only the downfield shift of the crown-ether bridge protons was observed, but also all the NH protons in ¹H NMR titration experiments (Fig. 6b and 7b). It was found that a Job's plot binding between






Fig. 7 Proposed negative allosteric behaviour of 4_e with Cl^- and K^+ ions. Partial ^1H NMR spectra of $4_e/\text{guest}$ ($H/G = 1:1$); (a) free 4_e ; (b) $4_e \supset \text{KSO}_3\text{CF}_3$; (c) $\text{Bu}_4\text{NCl} \subset [4_e \supset \text{K}^+]$; (d) $4_e \supset \text{Bu}_4\text{NCl}$. Solvent: CDCl_3 –DMSO (10 : 1, v/v). 300 MHz at 298 K. *Denotes the solvent peak.

receptor 4_e and K^+ ion exhibited a 1 : 1 stoichiometry and that the K_a value for the complexation with K^+ ion was determined to be $28\,536 (\pm 1998) \text{ M}^{-1}$ by UV-vis titration experiments in CH_2Cl_2 –DMSO (10 : 1, v/v) (Fig. S34 and S35[†]). These results suggest that the crown-5 ring of receptor 4_e binds K^+ ion. To seek more detailed information about the presence of an effective positive or negative allosteric effect between receptor $4_e \cdot \text{K}^+$ and Br^- or Cl^- ions, ^1H NMR spectroscopic and UV-vis titration experiments in CHCl_3 –DMSO (10 : 1, v/v) (Fig. S36[†]) were carried. Fig. 6 reveals that when Br^- ion were added to the solution of $[4_e \supset \text{KSO}_3\text{CF}_3]$ (Fig. 6c), the addition induces a downfield shift of 0.42 ppm ($\delta = 9.09$ to 9.51 ppm) for the NH_a protons, and upfield shifts of 0.85 ppm ($\delta = 8.95$ to 8.10 ppm) for the NH_b protons and of 0.29 ppm ($\delta = 8.10$ to 7.81 ppm) for the NH_c protons, while the chemical shifts for the crown-ether bridge protons did not change. These results suggested the formation of a heteroditopic dinuclear complex of the type $\text{Br}^- \subset [4_e \supset \text{K}^+]$ (Fig. 6c), and we propose a positive allosteric effect of receptor 4_e towards Br^- ions in the presence of K^+ ion by an ion-pair electrostatic interaction and a conformational change of the flexible thiocalix[4]arene cavity as shown in Fig. 6. On the other hand, Fig. 7 shows that when Cl^- ions were added to the solution of $[4_e \supset \text{KSO}_3\text{CF}_3]$ (Fig. 7c), this addition induces a downfield shift of 1.11 ppm ($\delta = 9.09$ to 10.2 ppm) for the NH_a protons and 0.04 ppm ($\delta = 8.10$ to 8.14 ppm) for the NH_c protons, and an upfield shift of 0.37 ppm ($\delta = 8.95$ to 8.58 ppm) for the NH_b protons, together with upfield shifts for the crown-ether bridge protons. Interestingly, when Cl^- ions were added to the solution of $[4_e \supset \text{KSO}_3\text{CF}_3]$ (Fig. 7c), the chemical shifts for the crown-ether bridge protons most closely matched the chemical shifts for the free crown-ether bridge protons

(Fig. 7c and d). These results suggested that the two urea groups in two *p*-nitrophenyl ureido moieties of receptor $4_e \cdot \text{K}^+$ bind the Cl^- ion by an ion-pair electrostatic interaction and a conformational change of the flexible thiocalix[4]arene cavity. This induces the decomplexation of the K^+ ion from the crown-5 ring of receptor 4_e because the Cl^- ion has a smaller ionic radius and therefore an increase in basicity in comparison with the Br^- ion, and a negative allosteric effect of receptor 4_e to Cl^- ion in the presence of K^+ ion as shown in Fig. 7 is proposed.

Conclusion

In summary, a new family of heteroditopic receptors (4_{a-e}) based on a thiocalix[4]arene in the 1,3-*alternate* conformation, which has two ureas moieties bearing various phenyl groups substituted with either electron-donating or -withdrawing groups at their *m*-, or *p*-positions, as well as a crown-ether moiety at the opposite side of thiocalix[4]arene cavity, has been synthesized. By using ^1H NMR spectroscopic and UV-vis titration experiments, receptor 4_e possessing an electron-withdrawing NO_2 group at the *p*-position has the most effective recognition ability towards the selected anions. The binding of K^+ ions and various anions at the crown-5 ring moiety and the two urea NH groups in two *p*-nitrophenyl ureido moieties, respectively, was investigated. The results indicated the complexation mode, and it was found that receptor 4_e was able to bind all of the anions tested, irrespective of their shape. Receptor 4_e exhibited highest selectivity towards F^- ion amongst all of the anions tested and indicated that this receptor might be a promising candidate as a colorimetric chemosensor. The appearance of positive and negative allosteric effects in receptor 4_e was also investigated by ^1H NMR and UV-vis titration experiments. Interestingly, the formation of a heteroditopic dinuclear complex of receptor 4_e with Br^- and K^+ ions by a positive allosteric effect could be observed. On the other hand, the fact that two urea NH groups in two *p*-nitrophenyl ureido moieties of receptor $4_e \cdot \text{K}^+$ bind the Cl^- ion, which then induces the decomplexation of the K^+ ion from the crown-5 ring, is indicative of a negative allosteric effect.

Experimental section

General

All melting points were determined with Yanagimoto MP-S1. ^1H -NMR spectra were determined at 300 MHz with a Nippon Denshi JEOL FT-300 NMR spectrometer with SiMe_4 as an internal reference; *J*-values are given in Hz. UV spectra were measured by a Shimadzu 240 spectrophotometer. Mass spectra were obtained on a Nippon Denshi JMS-01SG-2 mass spectrometer at an ionization energy of 70 eV using a direct inlet system through GLC. Elemental analyses were performed by Yanaco MT-5.

Materials

Unless otherwise stated, all other reagents used were purchased from commercial sources and used without further purification.



Compounds **1**¹³ and **2**¹² were prepared following the reported procedures.

Synthesis of compound 3

Compound **2** (1.0 g, 0.95 mmol) was put into a round-bottom flask and ethanol (120 mL), THF (120 mL) and hydrazine hydrate (14 mL, large excess) were added and refluxed for 48 h. After cooling, the solvents and excess hydrazine were removed under reduced pressure to give the crude product as a white solid. The residue was triturated sequentially with water and methanol and the product collected by filtration. Compound **3** was obtained 0.84 g (86%) as a white solid. M.p. 216–218 °C. IR: ν_{\max} (KBr)/cm⁻¹: 3421, 2961, 1670, 1438, 1263, 1091, 1019 and 801. ¹H NMR (300 MHz, CDCl₃): δ = 1.25 (18H, s, *t*Bu \times 2), 1.37 (18H, s, *t*Bu \times 2), 3.00 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 3.39 (4H, br, OCH₂ \times 2), 3.48 (4H, br, NH₂ \times 2), 3.60 (4H, broad s, OCH₂ \times 2), 3.96 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 4.55 (4H, s, OCH₂CO \times 2), 7.35 (4H, s, Ar-*H* \times 2), 7.41 (4H, s, Ar-*H* \times 2) and 7.54 (2H, s, NH \times 2) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 30.5 (CH₃), 33.5 (C(CH₃)₃), 64.9 (OCH₂), 67.4 (OCH₂), 69.2 (OCH₂), 70.5 (OCH₂), 72.6 (OCH₂), 126.2 (ArC), 126.4 (ArC), 126.5 (ArC), 126.7 (ArC), 146.5 (ArC), 146.7 (ArC), 153.6 (ArC), 155.4 (ArC) and 167.6 (CO) ppm. FABMS: m/z : 1023.38 (M⁺). C₅₂H₇₀N₄O₉S₄ (1023.39): calcd C 61.03, H 6.89, N 5.47. Found: C 61.33, H 6.79, N 5.57.

Synthesis of receptor 4a

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added phenyl isocyanate (38 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with hexane to give receptor **4a** as a white solid. Recrystallization from CHCl₃–CH₃CN (4 : 1) gave receptor **4a** (154 mg, 83%) as white solid. M.p. 202–205 °C. IR: ν_{\max} (KBr)/cm⁻¹: 3270, 2956, 1674, 1547, 1442, 1263, 1221, 1153, 1091, 799 and 751. ¹H NMR (300 MHz, CDCl₃–DMSO, 10 : 1): δ = 1.25 (18H, s, *t*Bu \times 2), 1.39 (18H, s, *t*Bu \times 2), 2.97 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 3.40 (4H, br, OCH₂ \times 2), 3.63 (4H, s, OCH₂ \times 2), 3.85 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 4.59 (4H, s, OCH₂CO \times 2), 6.95 (2H, t, J = 7.3 Hz, phenyl-*H* \times 2), 7.15 (4H, t, J = 7.6 Hz, phenyl-*H* \times 4), 7.31 (4H, d, J = 7.7 Hz, phenyl-*H* \times 2), 7.35 (4H, s, Ar-*H* \times 4), 7.48 (4H, s, Ar-*H* \times 4), 7.57 (2H, s, NH \times 2), 8.10 (2H, s, NH \times 2), 8.32 (2H, s, NH \times 2) ppm. ¹³C NMR (100 MHz, CDCl₃–DMSO, 10 : 1): δ = 29.9 (CH₃), 30.4 (CH₃), 33.5 (C(CH₃)₃), 33.5 (C(CH₃)₃), 64.9 (OCH₂), 67.5 (OCH₂), 69.0 (OCH₂), 70.6 (OCH₂), 72.6 (OCH₂), 118.4 (ArC), 120.4 (ArC), 121.8 (ArC), 125.6 (ArC), 126.1 (ArC), 126.3 (ArC), 127.1 (ArC), 127.5 (ArC), 128.0 (ArC), 128.2 (ArC), 137.3 (ArC), 146.4 (ArC), 147.5 (ArC), 153.7 (ArC), 154.0 (CO), 154.6 (ArC) and 167.5 (CO) ppm. FABMS: m/z : 1261.43 (M⁺). C₆₆H₈₀N₆O₁₁S₄ (1260.48): calcd C 62.83, H 6.39, N 6.66. Found: C 62.59, H 6.23, N 6.45.

Synthesis of receptor 4b

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added *p*-tolyl isocyanate (43 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with

EtOH to give receptor **4b** as a white solid. Recrystallization from CHCl₃–CH₃CN (2 : 1) gave receptor **4b** (163 mg, 86%) as white solid. M.p. 205–207 °C. IR: ν_{\max} (KBr)/cm⁻¹: 3283, 2955, 1678, 1547, 1444, 1266, 1207, 1151, 1089, 999 and 815. ¹H NMR (300 MHz, CDCl₃–DMSO, 10 : 1): δ = 1.27 (18H, s, *t*Bu \times 2), 1.39 (18H, s, *t*Bu \times 2), 2.28 (6H, s, CH₃ \times 2), 2.97 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 3.40 (4H, br, OCH₂ \times 2), 3.63 (4H, s, OCH₂ \times 2), 3.85 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 4.58 (4H, s, OCH₂CO \times 2), 6.96 (4H, d, J = 7.7 Hz, phenyl-*H* \times 4), 7.16 (4H, d, J = 7.7 Hz, phenyl-*H* \times 4), 7.35 (4H, s, Ar-*H* \times 4), 7.48 (4H, s, Ar-*H* \times 4), 7.51 (2H, s, NH \times 2), 8.10 (2H, s, NH \times 2), 8.22 (2H, s, NH \times 2) ppm. ¹³C NMR (100 MHz, CDCl₃–DMSO, 10 : 1): δ = 20.7 (CH₃), 30.9 (CH₃), 31.4 (CH₃), 34.4 (C(CH₃)₃), 34.5 (C(CH₃)₃), 65.9 (OCH₂), 68.6 (OCH₂), 70.0 (OCH₂), 71.6 (OCH₂), 73.6 (OCH₂), 119.4 (ArC), 126.6 (ArC), 127.0 (ArC), 127.3 (ArC), 128.2 (ArC), 129.0 (ArC), 129.5 (ArC), 131.9 (ArC), 135.7 (ArC), 136.1 (ArC), 147.4 (ArC), 148.5 (ArC), 154.4 (ArC), 154.8 (ArC), 155.1 (CO), 155.5 (ArC) and 168.5 (CO) ppm. FABMS: m/z : 1289.46 (M⁺). C₆₈H₈₄N₆O₁₁S₄ (1289.69): calcd C 63.33, H 6.56, N 6.52. Found: C 62.56, H 6.56, N 6.25.

Synthesis of receptor 4c

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added *p*-trifluoromethylphenyl isocyanate (59 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with EtOH to give receptor **4c** as a white solid. Recrystallization from CHCl₃–CH₃CN (1 : 1) gave receptor **4c** (164 mg, 80%) as white solid. M.p. 207–210 °C. IR: ν_{\max} (KBr)/cm⁻¹: 3283, 2959, 1687, 1548, 1445, 1266, 1158, 1091, 1068 and 840. ¹H NMR (300 MHz, CDCl₃–DMSO, 10 : 1): δ = 1.27 (18H, s, *t*Bu \times 2), 1.40 (18H, s, *t*Bu \times 2), 2.97 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 3.40 (4H, br, OCH₂ \times 2), 3.63 (4H, s, OCH₂ \times 2), 3.85 (4H, t, J = 9.1 Hz, OCH₂ \times 2), 4.61 (4H, s, OCH₂CO \times 2), 7.36 (4H, s, Ar-*H* \times 4), 7.39–7.42 (8H, m, phenyl-*H* \times 8), 7.49 (4H, s, Ar-*H* \times 4), 7.56 (2H, s, NH \times 2), 8.29 (2H, s, NH \times 2), 8.69 (2H, s, NH \times 2) ppm. ¹³C NMR (100 MHz, CDCl₃–DMSO, 10 : 1): δ = 30.9 (CH₃), 31.3 (CH₃), 34.4 (C(CH₃)₃), 34.5 (C(CH₃)₃), 66.1 (OCH₂), 68.5 (OCH₂), 69.9 (OCH₂), 71.6 (OCH₂), 73.5 (OCH₂), 118.1 (ArC), 122.9 (ArC), 123.9 (CF₃), 124.2 (CF₃), 125.6 (ArC), 125.8 (ArC), 125.9 (ArC), 126.4 (ArC), 126.9 (ArC), 127.0 (ArC), 128.2 (ArC), 147.4 (ArC), 148.4 (ArC), 154.6 (ArC), 154.8 (CO), 155.5 (ArC) and 167.5 (CO) ppm. FABMS: m/z : 1397.44 (M⁺). C₆₈H₇₈F₆N₆O₁₁S₄ (1397.63): calcd C 58.44, H 5.63, N 6.01. Found: C 58.62, H 5.53, N 6.13.

Synthesis of receptor 4d

To compound **3** (150 mg, 0.147 mmol) in THF (10 mL), was added 3,5-bis(trifluoromethyl)phenyl isocyanate (82 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with EtOH to give receptor **4d** as a white solid. Recrystallization from CHCl₃–CH₃CN (1 : 1) gave receptor **4d** (187 mg, 83%) as white solid. M.p. 208–210 °C. IR: ν_{\max} (KBr)/cm⁻¹: 3315, 2963, 1677, 1577, 1443, 1215, 1136, 1092, 1019 and 880. ¹H NMR (300 MHz, CDCl₃–DMSO, 10 : 1): δ = 1.32



(18H, s, *t*Bu \times 2), 1.39 (18H, s, *t*Bu \times 2), 3.01 (4H, t, J = 9.1 Hz, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.64 (4H, s, $\text{OCH}_2 \times 2$), 3.89 (4H, t, J = 9.1 Hz, $\text{OCH}_2 \times 2$), 4.63 (4H, s, $\text{OCH}_2\text{CO} \times 2$), 7.28 (2H, s, phenyl-*H* \times 2), 7.38 (4H, s, Ar-*H* \times 4), 7.42 (4H, s, phenyl-*H* \times 4), 7.49 (4H, s, Ar-*H* \times 4), 7.82 (2H, s, NH \times 2), 8.49 (2H, s, NH \times 2), 9.05 (2H, s, NH \times 2) ppm. ^{13}C NMR (100 MHz, CDCl_3 -DMSO, 10 : 1): δ = 30.8 (CH_3), 31.2 (CH_3), 34.3 ($\text{C}(\text{CH}_3)_3$), 34.4 ($\text{C}(\text{CH}_3)_3$), 65.8 (OCH_2), 67.9 (OCH_2), 69.7 (OCH_2), 71.4 (OCH_2), 73.4 (OCH_2), 115.3 (ArC), 117.7 (ArC), 121.6 (ArC), 124.3 (CF_3), 126.1 (ArC), 126.7 (ArC), 127.0 (ArC), 127.9 (ArC), 131.7 (ArC), 140.4 (ArC), 147.4 (ArC), 148.4 (ArC), 154.1 (ArC), 154.5 (ArC), 155.4 (CO), 155.5 (ArC) and 167.4 (CO) ppm. FABMS: m/z : 1533.48 (M^+). $\text{C}_{70}\text{H}_{76}\text{F}_{12}\text{N}_6\text{O}_{11}\text{S}_4$ (1533.63): calcd C 54.82, H 4.99, N 5.48. Found: C 54.63, H 5.05, N 5.35.

Synthesis of receptor 4e

To compound 3 (150 mg, 0.147 mmol) in THF (10 mL), was added *p*-nitrophenyl isocyanate (53 mg, 0.320 mmol) and the mixture was stirred for at room temperature for 24 h under argon. The resulting precipitate was collected by filtration, washed with EtOH to give receptor 4e as a pale yellow solid. Recrystallization from CHCl_3 - CH_3CN (3 : 1) gave receptor 4e (165 mg, 83%) as pale yellow solid. M.p. 212–215 °C. IR: ν_{max} (KBr)/ cm^{-1} : 3257, 2957, 1682, 1555, 1512, 1445, 1415, 1266, 1150, 1091 and 850. ^1H NMR (300 MHz, CDCl_3 -DMSO, 10 : 1): δ = 1.27 (18H, s, *t*Bu \times 2), 1.39 (18H, s, *t*Bu \times 2), 2.97 (4H, t, J = 9.1 Hz, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.63 (4H, s, $\text{OCH}_2 \times 2$), 3.85 (4H, t, J = 9.1 Hz, $\text{OCH}_2 \times 2$), 4.58 (4H, s, $\text{OCH}_2\text{CO} \times 2$), 7.40 (4H, s, Ar-*H* \times 4), 8.57 (4H, s, Ar-*H* \times 4), 7.58 (4H, d, J = 9.3 Hz, phenyl-*H* \times 4), 7.66 (2H, s, NH \times 2), 8.06 (4H, d, J = 9.3 Hz, phenyl-*H* \times 4), 8.40 (2H, s, NH \times 2), 9.08 (2H, s, NH \times 2) ppm. ^{13}C NMR (100 MHz, CDCl_3 -DMSO, 10 : 1): δ = 30.9 (CH_3), 31.3 (CH_3), 34.4 ($\text{C}(\text{CH}_3)_3$), 34.5 ($\text{C}(\text{CH}_3)_3$), 66.2 (OCH_2), 69.0 (OCH_2), 69.9 (OCH_2), 71.7 (OCH_2), 73.6 (OCH_2), 118.1 (ArC), 124.9 (ArC), 126.2 (ArC), 127.1 (ArC), 127.7 (ArC), 128.0 (ArC), 128.4 (ArC), 142.6 (ArC), 144.5 (ArC), 147.5 (ArC), 147.3 (ArC), 147.9 (ArC), 148.2 (ArC), 154.0 (ArC), 154.2 (CO), 155.7 (ArC) and 168.5 (CO) ppm. FABMS: m/z : 1351.57 (M^+). $\text{C}_{66}\text{H}_{78}\text{N}_8\text{O}_{15}\text{S}_4$ (1351.63): calcd C 58.65, H 5.82, N 8.29. Found: C 58.81, H 5.75, N 8.12.

Determination of the association constants

The association constants were determined by using ^1H NMR spectroscopic titration experiments in a constant concentration of host receptor (4.0×10^{-3} M) and varying the guest concentration (0 – 8.0×10^{-3} M). The ^1H NMR chemical shift of the urea protons (NH) signal was used as a probe. The association constant (K_a) for the complexes of receptor 4a–e were calculated by nonlinear curve-fitting analysis of the observed chemical shifts of the NH protons according to the literature procedure.¹⁴

^1H NMR titration experiments

A solution of Bu_4NX ($\text{X} = \text{F}, \text{Cl}, \text{Br}, \text{I}, \text{AcO}, \text{PhCOO}, \text{H}_2\text{PO}_4$) in CD_3CN (4.0×10^{-3} M) was added to a CDCl_3 solution of receptor 4a–e in the absence or presence of KSO_3CF_3 in an NMR tube. ^1H NMR spectra were recorded after addition of the reactants and the temperature of the NMR probe was kept

constant at 27 °C. The ^1H NMR spectroscopic data of representative complexes are given below:

Receptor 4a $\rightarrow \text{Cl}^-$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 2.97 (4H, br, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.63 (4H, br, $\text{OCH}_2 \times 2$), 3.85 (4H, br, $\text{OCH}_2 \times 2$), 4.59 (4H, s, $\text{OCH}_2\text{O} \times 2$), 7.89 (2H, br, $\text{NH}_c \times 2$), 8.10 (2H, br, $\text{NH}_b \times 2$) and 8.95 (2H, br, $\text{NH}_a \times 2$) ppm.

Receptor 4b $\rightarrow \text{Cl}^-$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 2.97 (4H, br, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.63 (4H, br, $\text{OCH}_2 \times 2$), 3.85 (4H, br, $\text{OCH}_2 \times 2$), 4.68 (4H, s, $\text{OCH}_2\text{O} \times 2$), 7.80 (2H, br, $\text{NH}_c \times 2$), 8.09 (2H, br, $\text{NH}_b \times 2$) and 8.63 (2H, br, $\text{NH}_a \times 2$) ppm.

Receptor 4c $\rightarrow \text{Cl}^-$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 2.97 (4H, br, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.63 (4H, br, $\text{OCH}_2 \times 2$), 3.85 (4H, br, $\text{OCH}_2 \times 2$), 4.68 (4H, s, $\text{OCH}_2\text{O} \times 2$), 8.01 (2H, br, $\text{NH}_c \times 2$), 8.20 (2H, br, $\text{NH}_b \times 2$) and 9.58 (2H, br, $\text{NH}_a \times 2$) ppm.

Receptor 4d $\rightarrow \text{Cl}^-$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 3.01 (4H, br, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.64 (4H, br, $\text{OCH}_2 \times 2$), 3.89 (4H, br, $\text{OCH}_2 \times 2$), 4.63 (4H, s, $\text{OCH}_2\text{O} \times 2$), 7.94 (2H, br, $\text{NH}_c \times 2$), 8.33 (2H, br, $\text{NH}_b \times 2$) and 9.70 (2H, br, $\text{NH}_a \times 2$) ppm.

Receptor 4e $\rightarrow \text{Cl}^-$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 2.97 (4H, br, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.63 (4H, br, $\text{OCH}_2 \times 2$), 3.85 (4H, br, $\text{OCH}_2 \times 2$), 4.60 (4H, s, $\text{OCH}_2\text{O} \times 2$), 8.10 (2H, br, $\text{NH}_c \times 2$), 8.18 (2H, br, $\text{NH}_b \times 2$) and 10.8 (2H, br, $\text{NH}_a \times 2$) ppm.

Receptor 4e $\rightarrow \text{K}^+$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 3.11 (4H, br, $\text{OCH}_2 \times 2$), 3.36–3.58 (4H, m, $\text{OCH}_2 \times 2$), 3.64–3.90 (4H, m, $\text{OCH}_2 \times 2$), 4.08 (4H, br, $\text{OCH}_2 \times 2$), 4.30–4.61 (4H, m, $\text{OCH}_2\text{O} \times 2$), 8.10 (2H, s, $\text{NH}_c \times 2$), 8.95 (2H, broad s, $\text{NH}_b \times 2$) and 9.09 (2H, broad s, $\text{NH}_a \times 2$) ppm.

$\text{Cl}^- \subset [\text{receptor } 4e \rightarrow \text{K}^+]$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 2.97 (4H, br, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.63 (4H, br, $\text{OCH}_2 \times 2$), 3.85 (4H, br, $\text{OCH}_2 \times 2$), 4.60 (4H, s, $\text{OCH}_2\text{O} \times 2$), 8.14 (2H, br, $\text{NH}_c \times 2$), 8.58 (2H, br, $\text{NH}_b \times 2$) and 10.2 (2H, br, $\text{NH}_a \times 2$) ppm.

Receptor 4e $\rightarrow \text{Br}^-$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 2.97 (4H, br, $\text{OCH}_2 \times 2$), 3.40 (4H, br, $\text{OCH}_2 \times 2$), 3.63 (4H, br, $\text{OCH}_2 \times 2$), 3.85 (4H, br, $\text{OCH}_2 \times 2$), 4.60 (4H, s, $\text{OCH}_2\text{O} \times 2$), 7.52 (2H, br, $\text{NH}_c \times 2$), 8.25 (2H, br, $\text{NH}_b \times 2$) and 9.27 (2H, br, $\text{NH}_a \times 2$).

$\text{Br}^- \subset [\text{receptor } 4e \rightarrow \text{K}^+]$. ^1H NMR (300 MHz, CHCl_3 -DMSO- CH_3CN , 10 : 1 : 1, v/v): δ = 3.11 (4H, br, $\text{OCH}_2 \times 2$), 3.36–3.58 (4H, m, $\text{OCH}_2 \times 2$), 3.64–3.90 (4H, m, $\text{OCH}_2 \times 2$), 4.08 (4H, br, $\text{OCH}_2 \times 2$), 4.30–4.61 (4H, m, $\text{OCH}_2\text{O} \times 2$), 7.81 (2H, br, $\text{NH}_c \times 2$), 8.10 (2H, br, $\text{NH}_b \times 2$) and 9.51 (2H, br, $\text{NH}_a \times 2$).

Crystallographic analysis of receptors 4b and 4e

Crystal data for 4b. $\text{C}_{68}\text{H}_{84}\text{N}_6\text{O}_{11}\text{S}_4 \cdot \frac{1}{2}(\text{H}_2\text{O}) \cdot \frac{1}{2}(\text{CHCl}_3)$, M_r = 1477.71. Monoclinic, $P2_1/n$; a = 18.8935 (13), b = 23.9302 (16), c = 33.589 (2) Å; β = 91.5063 (12)°; V = 15 181.2 (17) Å³; Z = 8; D_x = 1.293 Mg m⁻³; $F(000)$ = 6224; T = 210(2) K; μ (Mo-K α) = 0.34 mm⁻¹; λ = 0.71073 Å, crystal size 0.71 \times 0.54 \times 0.32 mm³. Crystals were colorless blocks. Diffraction data were measured on a Bruker APEX 2 CCD diffractometer equipped with graphite



monochromated MoK α radiation by thin-slice ω -scans.¹⁵ 134 900 measured reflections, 31 218 independent reflections ($R_{\text{int}} = 0.049$) to $\theta_{\text{max}} = 26.5^\circ$; 19 539 reflections with $I > 2\sigma(I)$. The structure was determined by direct methods using the SHELXS program and refined by the full-matrix least-squares method, on F^2 , in SHELXL-2013/14.^{16,17} The non-hydrogen atoms were refined with anisotropic thermal parameters. Hydrogen atoms on C were included in idealized positions and their U_{iso} values were set to ride on the U_{eq} values of the parent atoms. H atoms on N were freely refined. At the conclusion of the refinement, $wR_2 = 0.173$ (all data) and $R_1 = 0.056$ (observed data), 1903 parameters, $\Delta_{\text{max}} = 0.56 \text{ e}\text{\AA}^{-3}$; 465 restraints, $\Delta_{\text{min}} = -0.43 \text{ e}\text{\AA}^{-3}$. The platon squeeze procedure was used to model two of the three unique CHCl_3 molecules due to severe disorder.¹⁸ Two-fold disorder was modelled in some *t*Bu groups, in parts of one of the crown ether chains and the other CHCl_3 molecule. H atoms on water molecule O(23) could not be located in difference maps, so were not included in the model.[†]

Crystal data for 4c. $\text{C}_{66}\text{H}_{78}\text{N}_8\text{O}_{15}\text{S}_4 \cdot \frac{1}{2}(\text{CHCl}_3) \cdot 3(\text{MeCN})$, $M_r = 1534.44$. Monoclinic, $P2_1/c$; $a = 17.7980$ (10), $b = 26.7870$ (16), $c = 32.552$ (2) \AA ; $\beta = 96.384$ (4) $^\circ$; $V = 15\,423.1$ (16) \AA^3 ; $Z = 8$; $D_x = 1.322 \text{ Mg m}^{-3}$; $F(000) = 6472$; $T = 100$ (2) K; μ (Mo-K α) = 0.31 mm^{-1} ; $\lambda = 0.7749 \text{ \AA}$, crystal size $0.25 \times 0.25 \times 0.02 \text{ mm}^3$. Crystals were colorless plates. Diffraction data were measured on a Bruker APEX 2 CCD diffractometer at station 11.3.1 of the ALS using synchrotron radiation by thin-slice ω -scans.¹⁵ 155 885 measured reflections, 50 956 independent reflections ($R_{\text{int}} = 0.052$) to $\theta_{\text{max}} = 34.8^\circ$; 35 702 reflections with $I > 2\sigma(I)$. Structure solution with SHELXT and refinement as above.^{16,17} Hydrogen atoms on C and some N atoms were included in idealized positions and their U_{iso} values were set to ride on the U_{eq} values of the parent atoms. H atoms on the remaining N atoms were freely refined. At the conclusion of the refinement, $wR_2 = 0.294$ (all data) and $R_1 = 0.086$ (observed data), 2055 parameters, $\Delta_{\text{max}} = 2.44 \text{ e}\text{\AA}^{-3}$; 656 restraints, $\Delta_{\text{min}} = -1.86 \text{ e}\text{\AA}^{-3}$. The platon squeeze procedure was used to model four of the six unique MeCN molecules due to severe disorder.¹⁸ Two-fold disorder was modelled in some *t*Bu groups and in parts of one the crown ether chains and one $\text{HN-}p\text{-C}_6\text{H}_4\text{NO}_2$ group.[†]

Acknowledgements

This work was performed under the Cooperative Research Program of "Network Joint Research Center for Materials and Devices (Institute for Materials Chemistry and Engineering, Kyushu University)". We would like to thank the OTEC at Saga University and the International Cooperation Projects of Guizhou Province (no. 20137005) for financial support. CR thanks the EPSRC for a travel grant. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract no. DE-AC02-05CH11231.

Notes and references

- (a) C. D. Gutsche, *Calixarenes, An Introduction*, Royal Society of Chemistry, Cambridge, UK, 2008; (b) A. Ikeda and

- S. Shinkai, *Chem. Rev.*, 1997, **97**, 1713–1734; (c) D. Coquière, S. Le Gac, U. Darbost, O. Sènèque, I. Jabin and O. Reinaud, *Org. Biomol. Chem.*, 2009, **7**, 2485–2500; (d) K. Cottet, P. M. Marcos and P. J. Cragg, *Beilstein J. Org. Chem.*, 2012, **8**, 201–226; (e) L. Mutihac, J. H. Lee, J. S. Kim and J. Vicens, *Chem. Soc. Rev.*, 2011, **40**, 2777–2796; (f) L. Baldini, A. Casnati, F. Sansone and R. Ungaro, *Chem. Soc. Rev.*, 2007, **36**, 254–266; (g) J. S. Kim and D. T. Quang, *Chem. Rev.*, 2007, **107**, 3780–3799; (h) R. Joseph and C. P. Rao, *Chem. Rev.*, 2011, **111**, 4658–4702; (i) C. Capici, Y. Cohen, A. D'Urso, G. Gattuso, A. Notti, A. Pappalardo, S. Pappalardo, M. F. Parisi, R. Purrello, S. Slovak and V. Villari, *Angew. Chem., Int. Ed.*, 2011, **50**, 12162–12167; (j) C. Talotta, C. Gaeta, Z. Qi, C. A. Schalley and P. Neri, *Angew. Chem., Int. Ed.*, 2013, **52**, 7437–7441; (k) M.-X. Wang, *Acc. Chem. Res.*, 2012, **45**, 182–195.
- H. Kumagi, M. Hasegawa, S. Miyanari, Y. Sugawa, Y. Sato, T. Hori, S. Ueda, H. Kamiyama and S. Miyano, *Tetrahedron Lett.*, 1997, **38**, 3971–3972.
- (a) P. Lhoták, *Eur. J. Org. Chem.*, 2004, 1675–1692; (b) N. Morohashi, F. Narumi, N. Iki, T. Hattori and S. Miyano, *Chem. Rev.*, 2006, **106**, 5291–5316.
- (a) P. D. Beer and P. A. Gale, *Angew. Chem., Int. Ed.*, 2001, **40**, 486–516; (b) T. Nabeshima, T. Saiki and S. Kumitomo, *Org. Lett.*, 2002, **4**, 3207–3209; (c) T. Nabeshima, Y. Yoshihira, T. Saiki, S. Akine and E. Horn, *J. Am. Chem. Soc.*, 2003, **125**, 28–29; (d) A. Y. Zhukov, T. A. Fink, I. I. Stoikov and I. S. Antipin, *Russ. Chem. Bull.*, 2009, **58**, 1007–1014; (e) K. Mohr, J. Schmitz, R. Schrage, C. Trnkle and U. Holzgrabe, *Angew. Chem., Int. Ed.*, 2013, **52**, 508–516; (f) R. Nussinov and C.-J. Tsai, *Cell*, 2013, **153**, 293–305.
- (a) J.-Y. Kwon, Y.-J. Jang, S.-K. Kim, K.-H. Lee, J.-S. Kim and J. Yoon, *J. Org. Chem.*, 2004, **69**, 5155–5157; (b) D. Amilan Jose, D. K. Kumar, B. Ganguly and A. Das, *Org. Lett.*, 2004, **6**, 3445–3448; (c) J.-Y. Lee, E.-J. Cho, S. Mukamel and K.-C. Nam, *J. Org. Chem.*, 2004, **69**, 943–950; (d) D. Esteban-Gómez, L. Fabbrizzi and M. Licchelli, *J. Org. Chem.*, 2005, **70**, 5717–5720; (e) V. Thiagarajan, P. Ramamurthy, D. Thirumalai and V. T. Ramakrishnan, *Org. Lett.*, 2005, **7**, 657–660; (f) H. Lu, W. Xu, D. Zhang, C. Chen and D. Zhu, *Org. Lett.*, 2005, **7**, 4629–4632; (g) F. M. Pfeffer, T. Gunnlaugsson, P. Jensen and P. E. Kruger, *Org. Lett.*, 2005, **7**, 5357–5360; (h) L. Fang, W.-H. Chan, Y.-B. He, D. W.-J. Kwong and A. W.-M. Lee, *J. Org. Chem.*, 2005, **70**, 7640–7646; (i) T. Gunnlaugsson, P. E. Kruger, P. Jensen, J. Tierney, H. D. Paduka Ali and G. M. Hussey, *J. Org. Chem.*, 2005, **70**, 10875–10878; (j) A. Dahan, T. Ashkenazi, V. Kuznetsov, S. Makievski, E. Drug, L. Fadeev, M. Bramson, S. Schokoroy, E. Rozenshine-Kemelmakher and M. Gozin, *J. Org. Chem.*, 2007, **72**, 2289–2296; (k) S. Saha, A. Ghosh, P. Mahato, S. Mishra, S. K. Mishra, E. Suresh, S. Das and A. Das, *Org. Lett.*, 2010, **12**, 3406–3409.
- J. L. Sessler, P. A. Gale and W. S. Cho, *Anion Receptor Chemistry*, Royal Society of Chemistry, Cambridge, U.K., 2006.



- 7 (a) J. F. Zhang, Y. Zhou, J. Yoon and J. S. Kim, *Chem. Soc. Rev.*, 2011, **40**, 3416–3429; (b) C. Lodeiro, J. L. Capelo, J. C. Mejuto, E. Oliveira, H. M. Santos, B. Pedras and C. Nuñez, *Chem. Soc. Rev.*, 2010, **39**, 2948–2976; (c) L. E. Santos-Figueroa, M. E. Moragues, E. Climent, A. Agostini, R. Martínez-Mañez and F. Sancenón, *Chem. Soc. Rev.*, 2013, **42**, 3489–3613.
- 8 (a) R. M. F. Batista, E. Oliveira, S. P. G. Costa, C. Lodeiro and M. M. M. Raposo, *Org. Lett.*, 2007, **9**, 3201–3204; (b) F. Zapata, A. Caballero, A. Espinosa, A. Tárraga and P. Molina, *Org. Lett.*, 2008, **10**, 41–44; (c) R. D. Rasberry, M. D. Smith and K. D. Shimizu, *Org. Lett.*, 2008, **10**, 2889–2892; (d) C. Pérez-Casas and A. K. Yatsimirsky, *J. Org. Chem.*, 2008, **73**, 2275–2284; (e) J. P. Clare, A. Statnikov, V. Lynch, A. L. Sargent and J. W. Sibert, *J. Org. Chem.*, 2009, **74**, 6637–6646; (f) Q.-S. Lu, L. Dong, J. Zhang, J. Li, L. Jiang, Y. Huang, S. Qin, C.-W. Hu and X.-Q. Yu, *Org. Lett.*, 2009, **11**, 669–672; (g) S. Goswami, D. Sen and N. K. Das, *Org. Lett.*, 2010, **12**, 856–859; (h) A. Aldrey, C. Núñez, V. García, R. Bastida, C. Lodeiro and A. Macías, *Tetrahedron*, 2010, **66**, 9223–9230; (i) P. Dydio, T. Zieliński and J. Jurczak, *Org. Lett.*, 2010, **12**, 1076–1078; (j) V. K. Bhardwaj, S. Sharma, N. Singh, M. S. Hundal and G. Hundal, *Supramol. Chem.*, 2011, **23**, 790–800; (k) G.-W. Lee, N.-K. Kim and K.-S. Jeong, *Org. Lett.*, 2011, **13**, 3024–3027; (l) H. M. Chawla, S. N. Sahu, R. Shrivastava and S. Kumar, *Tetrahedron Lett.*, 2012, **53**, 2244–2247; (m) S. Goswami, A. Manna, S. Paul, K. Aich, A. K. Das and S. Chakraborty, *Tetrahedron Lett.*, 2013, **54**, 1785–1789; (n) K. Pandurangan, J. A. Kitchen and T. Gunnlaugsson, *Tetrahedron Lett.*, 2013, **54**, 2770–2775; (o) S. Areti, J. K. Khedkar, R. Chilukula and C. P. Rao, *Tetrahedron Lett.*, 2013, **54**, 5629–5634; (p) C. Jin, M. Zhang, C. Deng, Y. Guan, J. Gong, D. Zhu, Y. Pan, J. Jiang and L. Wang, *Tetrahedron Lett.*, 2013, **54**, 796–801.
- 9 (a) K. Lang, P. Cuřínová, M. Dudič, P. Prošcová, I. Stibor, V. Šťastný and P. Lhoták, *Tetrahedron Lett.*, 2005, **46**, 4469–4472; (b) P. Lhoták, J. Svoboda and I. Stibor, *Tetrahedron Lett.*, 2006, **62**, 1253–1257; (c) J. Kroupa, I. Stibor, M. Pojarová, M. Tkadlecová and P. Lhoták, *Tetrahedron*, 2008, **64**, 10075–10079; (d) O. Kundrat, H. Dvorakova, I. Cisarova, M. Pojarova and P. Lhoták, *Org. Lett.*, 2009, **11**, 4188–4191; (e) O. Kundrat, I. Cisarova, S. Böhm, M. Pojarova and P. Lhoták, *J. Org. Chem.*, 2009, **74**, 4592–4596; (f) O. Kundrat, H. Dvorakova, V. Eigner and P. Lhoták, *J. Org. Chem.*, 2010, **75**, 407–411; (g) O. Kundrat, J. Kroupa, S. Böhm, J. Budka, V. Eigner and P. Lhoták, *J. Org. Chem.*, 2010, **75**, 8372–8375; (h) O. Kundrat, V. Eigner, P. Cuřínová, J. Kroupa and P. Lhoták, *Tetrahedron*, 2011, **67**, 8367–8372; (i) O. Kundrat, V. Eigner, H. Dvorakova and P. Lhoták, *Org. Lett.*, 2011, **13**, 4032–4035; (j) P. Slavik, M. Dudic, K. Flidrova, J. Sykora, I. Cisarova, M. Pojarova and P. Lhoták, *Org. Lett.*, 2012, **14**, 3628–3631; (k) O. Kundrat, H. Dvorakova, S. Böhm, V. Eigner and P. Lhoták, *J. Org. Chem.*, 2012, **77**, 2272–2278.
- 10 (a) V. Bhalla, M. Kumar, H. Katagiri, T. Hattori and S. Miyano, *Tetrahedron Lett.*, 2005, **46**, 121–124; (b) V. Bhalla, J. N. Babu, M. Kumar, T. Hattori and S. Miyano, *Tetrahedron Lett.*, 2007, **48**, 1581–1585; (c) V. Bhalla, R. Kumar, M. Kumar and A. Dhir, *Tetrahedron*, 2007, **63**, 11153–11159; (d) A. Dhir, V. Bhalla and M. Kumar, *Org. Lett.*, 2008, **10**, 4891–4894; (e) R. Kumar, V. Bhalla and M. Kumar, *Tetrahedron*, 2008, **64**, 8095–8101; (f) R. K. Mahajan, R. Kaur, V. Bhalla, M. Kumar, T. Hattori and S. Miyano, *Sens. Actuators, B*, 2008, **130**, 290–294; (g) J. N. Babu, V. Bhalla, M. Kumar, R. K. Mahajan and R. K. Puri, *Tetrahedron Lett.*, 2008, **49**, 2772–2775; (h) M. Kumar, A. Dhir and V. Bhalla, *Org. Lett.*, 2009, **11**, 2567–2570; (i) M. Kumar, R. Kumar and V. Bhalla, *Tetrahedron*, 2009, **65**, 4340–4344; (j) M. Kumar, A. Dhir and V. Bhalla, *Org. Lett.*, 2009, **11**, 2567–2570; (k) M. Kumar, R. Kumar and V. Bhalla, *Tetrahedron Lett.*, 2010, **51**, 5559–5562; (l) M. Kumar, R. Kumar and V. Bhalla, *Org. Lett.*, 2011, **13**, 366–369; (m) M. Kumar, R. Kumar and V. Bhalla, *Org. Biomol. Chem.*, 2011, **9**, 8237–8245; (n) M. Kumar, R. Kumar and V. Bhalla, *Org. Lett.*, 2011, **13**, 366–369; (o) M. Kumar, R. Kumar and V. Bhalla, *Tetrahedron Lett.*, 2013, **54**, 1524–1527.
- 11 (a) C. Perez-Casas and T. Yamato, *J. Inclusion Phenom. Macrocyclic Chem.*, 2005, **53**, 1–8; (b) T. Yamato, C. Perez-Casas, H. Yamamoto, M. R. J. Elsegood, S. H. Dale and C. Redshaw, *J. Inclusion Phenom. Macrocyclic Chem.*, 2006, **54**, 261–269; (c) C. Perez-Casas, S. Rahman, N. Begum, Z. Xi and T. Yamato, *J. Inclusion Phenom. Macrocyclic Chem.*, 2008, **60**, 173–185; (d) X.-L. Ni, X. Zeng, C. Redshaw and T. Yamato, *J. Org. Chem.*, 2011, **76**, 3358–3370; (e) X.-L. Ni, X. Zeng, C. Redshaw and T. Yamato, *Tetrahedron*, 2011, **67**, 3248–3253; (f) X.-L. Ni, J. Tahara, S. Rahman, X. Zeng, D. L. Hughes, C. Redshaw and T. Yamato, *Chem.-Asian J.*, 2012, **7**, 519–527; (g) X.-L. Ni, H. Cong, A. Yoshizawa, S. Rahman, H. Tomiyasu, U. Rayhan, X. Zeng and T. Yamato, *J. Mol. Struct.*, 2013, **1046**, 110–115.
- 12 F. W. B. van Leewen, H. Beijleveld, H. Kooijman, A. L. Spek, W. Verboom and D. N. Reinhoudt, *J. Org. Chem.*, 2004, **69**, 3928–3936.
- 13 N. Iki, N. Morohashi, F. Narumi, T. Fujimoto, T. Suzuki and S. Miyano, *Tetrahedron Lett.*, 1999, **40**, 7337–7341.
- 14 H. A. Benesi and J. H. Hildebrand, *J. Am. Chem. Soc.*, 1949, **71**, 2703–2707.
- 15 APEX 2 and SAINT, Software for CCD diffractometers, Bruker AXS Inc., Madison, USA, 2011.
- 16 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Crystallogr.*, 2008, **64**, 112–122.
- 17 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Adv.*, 2015, **71**, 3–8.
- 18 A. L. Spek, *Acta Crystallogr., Sect. A: Found. Crystallogr.*, 1990, **46**, C34.

